This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Ono Pharmaceutical Co., Ltd.. Active years: 2021-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2024
Title: Satomi Imaide: Innovator in Therapeutic Compounds
Introduction
Satomi Imaide is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of therapeutic compounds, particularly in the area of S1P5 receptor agonistic activity. With a total of 2 patents, her work is paving the way for advancements in treating neurodegenerative diseases.
Latest Patents
Imaide's latest patents focus on compounds that exhibit S1P5 receptor agonistic activity. One of her notable inventions is a compound represented by the general formula (V), which demonstrates an improved balance of agonist activity against the S1P receptor. This compound has the potential to serve as a therapeutic agent for S1P-mediated diseases, including schizophrenia and Binswanger's disease, as well as other neurodegenerative conditions.
Career Highlights
Satomi Imaide is currently employed at Ono Pharmaceutical Co., Ltd., where she continues to innovate and develop new therapeutic solutions. Her expertise in receptor agonistic activity has positioned her as a key player in the pharmaceutical industry.
Collaborations
Imaide collaborates with esteemed colleagues such as Toshihide Watanabe and Kensuke Kusumi, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Satomi Imaide's work in developing therapeutic compounds showcases her dedication to addressing complex medical challenges. Her contributions are vital in the ongoing quest for effective treatments for neurodegenerative diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile